Charles Barr, MD
Ophthalmology · Louisville, KYNPI 1770518409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $844 and has fallen 60.2% since, to $336 in 2025.
Across 71 payments — averaging $54.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$654
- Regeneron Healthcare Solutions, Inc.$605
- Alcon$503
- Genentech USA, Inc.$441
- AbbVie$228
- Apellis Pharmaceuticals, Inc.$221
- plus $1K from 12 others
Across 7 payments — averaging $7186.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$25K
- Regeneron$25K
What the payments were for
- Food & beverage$3,845100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 6 | $654 |
| Regeneron Healthcare Solutions, Inc. | 12 | $605 |
| Alcon | 4 | $503 |
| Genentech USA, Inc. | 14 | $441 |
| AbbVie(2 entities) | 8 | $228 |
| Apellis Pharmaceuticals, Inc. | 6 | $221 |
| Novartis | 2 | $180 |
| Alimera Sciences, Inc. | 8 | $151 |
| Glaukos Corporation | 1 | $142 |
| Amgen | 1 | $125 |
| Aerie Pharmaceuticals, Inc. | 1 | $122 |
| Genentech, Inc. | 1 | $122 |
| Kala Pharmaceuticals, Inc. | 1 | $120 |
| Eyepoint US, Inc. | 1 | $110 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $45 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Harrow Eye, LLC | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,845 in reported general payments places this provider in the 75th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 26 | $1,301 |
| Prednisolone Acetate | 27 | $1,203 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $534 |
| Latanoprost | 34 | $237 |
| Timolol Maleate | 19 | $70 |
| Brimonidine Tartrate | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Louisville
- Jeremy ClarkLouisville$131K
- Guruprasad PattarLouisville$36K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Inder SingalLouisville$9K
- Rishi KumarLouisville$8K
- Frank BurnsLouisville$8K
- Steven BloomLouisville$6K
- Sharmini BalakrishnanLouisville$6K
- Sergei DmitrukLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.